. 2016 Feb 6;7(13):15566–15576. doi: 10.18632/oncotarget.7216

Table 3. Risk factors related to EFS and OS for patients with ovarion CCC.

Parameter	Relapse^a		P value^b	P value^c	HR^d (95% CI^e)	DOD		P value^b	P value^c	HR^d (95% CI)
Parameter	+	−	P value^b	P value^c	HR^d (95% CI^e)	+	−	P value^b	P value^c	HR^d (95% CI)
Age
≤50	45	74	0.944			28	100	0.297
>50	87	135	0.944			42	205	0.297
Optimal CRS
Optimal	111	207	<0.001			47	290	<0.001	0.001	2.48 (1.46-2.41)
Suboptimal	21	2	<0.001			23	15	<0.001	0.001	2.48 (1.46-2.41)
FIGO Stage
I+II	43	180	<0.001	<0.001	7.79 (5.36-11.33)	14	209	<0.001	<0.001	6.91 (3.72-12.84)
III+IV	89	29	<0.001	<0.001	7.79 (5.36-11.33)	56	96	<0.001	<0.001	6.91 (3.72-12.84)
Endometriosis
+	39	86	0.058			18	114	0.072
−	93	123	0.058			52	191	0.072
Ascites
+	53	76	0.129			24	115	0.897
−	79	133	0.129			46	190	0.897
Lymphadenectomy
+	92	144	0.827			46	213	0.407
−	40	65	0.827			24	92	0.407
LNM
+	31	38	0.129			20	54	0.039
−	61	107	0.129			26	160	0.039
First line chemotherapy
Taxane and platinum	96	144	0.557			50	214	0.835
Other regimens	36	65	0.557			20	91	0.835
Pretreatment CA-125 (U/mL)
≤35	23	55	0.060			11	68	0.176
>35	109	154	0.060			59	237	0.176

Note:

Thirty-two patients with persisitent disease were not included in this analysis

Log rank test

Cox proportional hazards model

Hazard ratios

Confidence intervals.